Microvascular density in lymphomas - evaluation methods and clinical impact

Česká verzia

Authors: Pavla Veselá ¹; Zbyněk Tonar ²; Ludmila Boudová ¹
Authors place of work: Šiklův ústav patologie, Fakultní nemocnice a Lékařská fakulta UK v Plzni ¹; Ústav histologie a embryologie a Biomedicínské centrum LF UK v Plzni ²
Published in the journal: Čes.-slov. Patol., 51, 2015, No. 2, p. 94-98
Category: Přehledový článek

Summary

In recent years antiangiogenic therapy has become a part of treatment protocols of solid tumors as well as of lymphomas. This is why tumor vascularization has been explored, the most important parameters to describe it being the microvascular density and immunohistochemical assessment of the expression of VEGF (vascular endothelial growth factor) and of its receptors. This review summarizes various methods of assessment of the microvascular density and the prognostic impact of microvascular density in lymphomas.

Keywords:
microvascular density - lymphoma - prognosis

Zdroje

1. Folkman J. Tumor angiogenesis factor. Cancer Res 1974; 34: 2109-2113.

2. Klener P. Angiogeneze jako součást nádorového „ekosystému“ a možnosti jejího ovlivnění. Klin Onkol 2010; 23(1): 14-20.

3. Turley H, Scott PA, Watts VM, Bicknell R, Harris AL, Gatter KC. Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J Pathol 1998; 186: 313-318.

4. Wolfesberger B, Guija de Arespacohaga A, Willmann M, et al. Expression of vascular endothelial growth factor and its receptors in canine lymphomas. J Comp Pathol 2007; 137(1): 30-40.

5. Quinn TP, Peters KG, De Vries C, Ferrara N, Williams LT. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 1993; 90: 7533-7537.

6. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9(6): 669-676.

7. Rahimi N. VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Front Biosci 2006; 11: 818-829.

8. Roskoski R Jr. VEGF receptor-tyrosine kinases: structure and regulation. Biochem Biophys Res Commun 2008; 375: 287-291.

9. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006; 39: 469-478.

10. Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996; 32A(14): 2474-2484.

11. Nico B, Benagiano V, Mangieri D, Maruotti N, Vacca A, Ribatti D. Evaluation of microvascular density in tumors: pro and contra. Histol Histopathol 2008; 23: 601-607.

12. Norrby K, Ridell B. Tumour-type-specific capillary endothelial cell stainability in malignant B-cell lymphomas using antibodies against CD31, CD34 and Factor VIII. AMPIS 2003; 111: 483-489.

13. Tichý M, Tichá V, Ščudla V, Šváchová M, Zapletalová J. Analýza angiogeneze v kostní dřeni u plazmocytárního myelomu. Cesk Patol 2010; 46(1): 15-19.

14. Sugita Y, Takase Y, Mori D, Tokunaga O, Nakashima A, Shigemori M. Endoglin (CD 105) is expressed on endothelial cells in the primary central nervous system lymphomas and correlates with survival. J Neurooncol 2007; 82: 249-256.

15. Vermeulen PB, Gasparini G, Fox SB, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002; 38: 1564-1579.

16. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.

17. Fox SB, Harris AL. Histological quantitation of tumour angiogenesis. AMPIS 2004; 112(7-8): 413-430.

18. Tonar Z, Egger GF, Witter K, Wolfesberger B. Quantification of microvessels in canine lymph nodes. Microsc Res Tech 2008; 71: 760-772.

19. Preusser M, Heinzl H, Gelpi E, et al. Histopathologic assessment of hot-spot microvessel density and vascular patterns in glioblastoma: Poor observer agreement limits clinical utility as prognostic factors-A translational research project of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Cancer 2006; 107: 162-170.

20. Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 1994; 73: 678-687.

21. Veselá P, Tonar Z, Šálek D, et al. Microvessel density of mantle cell lymphoma. A retrospective study of its prognostic role and the correlation with the Ki-67 and the mantle cell lymphoma international prognostic index in 177 cases. Virchows Arch 2014; 465(5): 587-597.

22. Rana C, Sharma S, Agrawal V, Singh U. Bone marrow angiogenesis in multiple myeloma and its correlation with clinicopathological factors. Ann Hematol 2010; 89: 789-794.

23. Kašparová P, Smolej L. Angiogeneze v kostní dřeni u pacientů s chronickou lymfocytární leukémií. Cesk Patol 2007; 43(2): 50–58.

24. Chantrain CF, DeClerck YA, Groshen S, McNamara G. Computerized quantification of tissue vascularization using high-resolution slide scanning of whole tumor sections. J Histochem Cytochem 2003; 51(2): 151-158.

25. Liu W, Xu J, Wang M, Wang Q, Bi Y, Han M. Tumor-derived vascular endothelial growth factor (VEGF)-a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway. Int J Oncol 2011; 39(5): 1213-1220.

26. Liu YA, Pan ST, Hou YC, et al. 3-D Visualization and Quantitation of Microvessels in Transparent Human Colorectal Carcinoma. PLoS One 2013; 8(11): e81857.

27. Jorgensen JM, Sorensen FB, Bendix K, et al. Angiogenesis in non-Hodgkin‘s lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma 2007; 48(3): 584-595.

28. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, chalkley count, and computer image analysis. J Pathol 1995; 177(3): 275-283.

29. Ribatti D, Vacca A, Nico B, Fanelli M, Roncali L, Dammacco F. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin‘s lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol 1996; 56(1-2): 45-53.

30. Ridell B, Norrby K. Intratumoral microvascular density in malignant lymphomas of B-cell origin. AMPIS 2001; 109: 66-72.

31. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60(5): 1388-1393.

32. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn’t tell us. J Natl Cancer Inst 2002; 94(12): 883-893.

33. Tzankov A, Heiss S, Ebner S, et al. Angiogenesis in nodal B cell lymphomas: a high throughput study. J Clin Pathol 2007; 60: 476-482.

34. Gratzinger D, Zhao S, Tibshirani RJ, et al. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest 2008; 88: 38-47.

35. Cardesa-Salzmann TM, Colomo L, Gutierrez G, et al. High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica 2011; 96(7): 996-1001.

36. Korkolopoulou P, Thymara I, Kavantzas N, et al. Angiogenesis in Hodgkin’s lymphoma: a morphometric approach in 286 patients with prognostic implications. Leukemia 2005; 19: 894-900.

37. Koster A, van Krieken JH, MacKenzie MA, et al. Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res 2005; 11: 154-161.

38. Taskinen M, Jantunen E, Kosma VM, Bono P, Karjalainen-Lindsberg ML, Leppä S. Prognostic impact of CD31-positive microvessel density in follicular lymphoma patients treated with immunochemotherapy. Eur J Cancer 2010; 46(13): 2506-2512.

39. Smolej L, Kašparová P. Choice of endothelial marker is crucial for assessment of bone marrow microvessel density in chronic lymphocytic leukemia. AMPIS 2008; 116(12): 1058-1062.

40. Antic D, Jovanovic MP, Fekete MD, Cokic V. Assessment of bone marrow microvessel density in chronic lymphocytic leukemia. Appl Immunohistochem Mol Morphol 2010; 18(4): 353-356.

41. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341(21): 1565-1571.

42. Gundersen HJG. Notes on the estimation of numerical density of arbitrary particles. The edge effects. J Microsc 1977; 111: 219-223.